Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

BACKGROUND: SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme 2, which can be upregulated by inhibitors of the renin–angiotensin system (RAS). We aimed to test our hypothesis that discontinuation of chronic treatment with ACE-inhibitors (ACEIs) or angiotensin II receptor block...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Axel, Schreinlechner, Michael, Sappler, Nikolay, Dolejsi, Theresa, Tilg, Herbert, Aulinger, Benedikt A, Weiss, Günter, Bellmann-Weiler, Rosa, Adolf, Christian, Wolf, Dominik, Pirklbauer, Markus, Graziadei, Ivo, Gänzer, Hannes, von Bary, Christian, May, Andreas E, Wöll, Ewald, von Scheidt, Wolfgang, Rassaf, Tienush, Duerschmied, Daniel, Brenner, Christoph, Kääb, Stefan, Metzler, Bernhard, Joannidis, Michael, Kain, Hans-Ulrich, Kaiser, Norbert, Schwinger, Robert, Witzenbichler, Bernhard, Alber, Hannes, Straube, Florian, Hartmann, Niels, Achenbach, Stephan, von Bergwelt-Baildon, Michael, von Stülpnagel, Lukas, Schoenherr, Sebastian, Forer, Lukas, Embacher-Aichhorn, Sabine, Mansmann, Ulrich, Rizas, Konstantinos D, Massberg, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195495/
https://www.ncbi.nlm.nih.gov/pubmed/34126053
http://dx.doi.org/10.1016/S2213-2600(21)00214-9

Ejemplares similares

Ejemplares similares